Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib maintenance after chemoradiation for unresectable EGFR-mutated stage III non-small cell lung cancer
jRCT2080224097Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Osimertinib maintenance with Placebo maintenance (2 arms). Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224097.